Compounds > macrostemonoside a
Page last updated: 2024-11-08

macrostemonoside a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

macrostemonoside A: from Allium macrostemon Bung; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
AlliumgenusA genus of the plant family Amaryllidaceae. Many produce pungent, often bacteriostatic and physiologically active compounds and are used as VEGETABLES; CONDIMENTS; and medicament, the latter in traditional medicine.[MeSH]AmaryllidaceaeA family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH]
Allium macrostemonspecies[no description available]AmaryllidaceaeA family of herbaceous plants with bulbs or rhizomes in the order Asparagales.[MeSH]

Cross-References

ID SourceID
PubMed CID197480
MeSH IDM0215402

Synonyms (5)

Synonym
macrostemonoside a
beta-d-galactopyranoside, (3-beta,5alpha,25r)-spirostan-3-yl o-beta-d-glucopyranosyl-(1-2)-o-(beta-d-glucopyranosyl-(1-3))-o-beta-d-glucopyranosyl-(1-4)-
tigogenin-3-o-beta-d-glucopyranosyl(1-2)(beta-d-glucopyranosyl(1-3))-beta-d-glucopyranosyl(1-4)-beta-d-galactopyranoside
143049-26-7
(2s,3r,4s,5s,6r)-2-[(2s,3r,4s,5s,6s)-5-hydroxy-6-(hydroxymethyl)-2-[(4s,5'r,7s,8r,9s,13s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-yl]-2,3-bis[[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]o
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.76 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		2.0410aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		2.0310aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
sb 203580
[no description available]		2.0310imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
beta-escin
[no description available]		2.9440
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.0810
Colorectal Cancer
[description not available]		07.0810
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.0810
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0410
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.0410
Hyperlipemia
[description not available]		02.0410
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		07.0410
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.0410
Obesity
A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).		07.0410